A detailed history of D. E. Shaw & Co., Inc. transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 4,384,677 shares of HRTX stock, worth $6.93 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,384,677
Holding current value
$6.93 Million
% of portfolio
0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.73 - $3.67 $901,852 - $1.91 Million
521,302 Added 13.49%
4,384,677 $8.73 Million
Q2 2024

Aug 14, 2024

BUY
$2.32 - $3.86 $2.71 Million - $4.51 Million
1,168,329 Added 43.35%
3,863,375 $13.5 Million
Q1 2024

May 15, 2024

BUY
$1.71 - $3.06 $2.4 Million - $4.3 Million
1,404,049 Added 108.76%
2,695,046 $7.47 Million
Q4 2023

Feb 14, 2024

BUY
$0.54 - $1.82 $564,690 - $1.9 Million
1,045,724 Added 426.35%
1,290,997 $2.19 Million
Q3 2023

Nov 14, 2023

SELL
$0.97 - $1.8 $100,576 - $186,636
-103,687 Reduced 29.71%
245,273 $252,000
Q2 2023

Aug 14, 2023

SELL
$1.11 - $2.88 $413,055 - $1.07 Million
-372,122 Reduced 51.61%
348,960 $404,000
Q1 2023

May 15, 2023

SELL
$1.51 - $3.25 $99,656 - $214,493
-65,998 Reduced 8.39%
721,082 $1.09 Million
Q4 2022

Feb 14, 2023

SELL
$2.25 - $4.67 $253,104 - $525,332
-112,491 Reduced 12.5%
787,080 $1.97 Million
Q3 2022

Nov 14, 2022

SELL
$2.66 - $5.37 $1.9 Million - $3.84 Million
-715,411 Reduced 44.3%
899,571 $3.8 Million
Q2 2022

Aug 15, 2022

SELL
$2.3 - $6.29 $964,268 - $2.64 Million
-419,247 Reduced 20.61%
1,614,982 $4.51 Million
Q1 2022

May 16, 2022

BUY
$4.63 - $9.94 $3.17 Million - $6.8 Million
683,738 Added 50.63%
2,034,229 $11.6 Million
Q4 2021

Feb 14, 2022

SELL
$8.35 - $12.6 $680,007 - $1.03 Million
-81,438 Reduced 5.69%
1,350,491 $12.3 Million
Q3 2021

Nov 15, 2021

SELL
$10.13 - $15.0 $5.39 Million - $7.98 Million
-532,221 Reduced 27.1%
1,431,929 $15.3 Million
Q2 2021

Aug 16, 2021

SELL
$13.27 - $18.48 $3.23 Million - $4.5 Million
-243,240 Reduced 11.02%
1,964,150 $30.5 Million
Q1 2021

May 17, 2021

SELL
$14.49 - $20.72 $780,837 - $1.12 Million
-53,888 Reduced 2.38%
2,207,390 $35.8 Million
Q4 2020

Feb 16, 2021

BUY
$14.61 - $22.14 $2.46 Million - $3.73 Million
168,612 Added 8.06%
2,261,278 $47.9 Million
Q3 2020

Nov 16, 2020

SELL
$13.67 - $17.77 $352,357 - $458,039
-25,776 Reduced 1.22%
2,092,666 $31 Million
Q2 2020

Aug 14, 2020

SELL
$10.89 - $21.47 $2.25 Million - $4.44 Million
-206,661 Reduced 8.89%
2,118,442 $31.2 Million
Q1 2020

May 15, 2020

SELL
$10.23 - $24.56 $5.32 Million - $12.8 Million
-519,946 Reduced 18.28%
2,325,103 $27.3 Million
Q4 2019

Feb 14, 2020

BUY
$17.42 - $26.61 $21 Million - $32.1 Million
1,207,750 Added 73.76%
2,845,049 $66.9 Million
Q3 2019

Nov 14, 2019

BUY
$16.36 - $21.39 $4.34 Million - $5.67 Million
265,008 Added 19.31%
1,637,299 $30.3 Million
Q2 2019

Aug 14, 2019

SELL
$16.93 - $26.22 $1.68 Million - $2.6 Million
-99,305 Reduced 6.75%
1,372,291 $25.5 Million
Q1 2019

May 15, 2019

BUY
$23.15 - $28.34 $9.67 Million - $11.8 Million
417,588 Added 39.62%
1,471,596 $36 Million
Q4 2018

Feb 14, 2019

BUY
$22.03 - $32.01 $10.4 Million - $15.1 Million
473,127 Added 81.45%
1,054,008 $27.3 Million
Q3 2018

Nov 14, 2018

BUY
$30.0 - $40.85 $4.28 Million - $5.83 Million
142,648 Added 32.55%
580,881 $18.4 Million
Q2 2018

Aug 14, 2018

SELL
$26.4 - $42.0 $14.2 Million - $22.6 Million
-537,780 Reduced 55.1%
438,233 $17 Million
Q1 2018

May 15, 2018

BUY
$18.43 - $28.8 $8.85 Million - $13.8 Million
480,381 Added 96.92%
976,013 $26.9 Million
Q4 2017

Feb 14, 2018

BUY
$14.8 - $18.85 $3.78 Million - $4.82 Million
255,457 Added 106.36%
495,632 $8.97 Million
Q3 2017

Nov 14, 2017

BUY
$14.65 - $16.85 $3.52 Million - $4.05 Million
240,175
240,175 $3.88 Million

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $188M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.